HeartBeam Inc. (NASDAQ: BEAT) has released its second-quarter 2026 financial and operational results, showcasing significant strides in its heart attack detection program and commercial launch efforts. The company completed enrollment of 134 patients in its ALIGN-ACS pilot study ahead of schedule, with full results expected to be presented at TCT 2026, and has surpassed 50% enrollment in its 500-patient HEADSTART-ACS pilot study. These studies are critical to validating the company's innovative 3D ECG technology, which aims to enable portable, cable-free detection of heart attacks outside traditional medical facilities.
In addition to clinical progress, HeartBeam has completed a working prototype of its 12-lead ECG extended wear patch, marking a major milestone in product development. The company has also signed multiple commercial agreements across four targeted U.S. geographies, shipped its first orders, and onboarded initial patients, signaling a successful initial commercial launch. This progress positions HeartBeam to capitalize on the growing demand for remote cardiac monitoring solutions, especially as healthcare systems increasingly focus on early detection and prevention of acute cardiac events.
Financially, HeartBeam reported a second-quarter net loss of $5 million, or $0.10 per basic and diluted share, consistent with the prior year's net loss of $5 million, or $0.15 per share. As of June 30, 2026, the company held $8.8 million in cash, cash equivalents, and restricted cash. Importantly, HeartBeam expects its full-year 2026 net operating cash outflow to be below $14 million, and the company has extended its cash runway into 2027. This financial stability provides the company with the resources needed to continue its clinical trials and commercial expansion without immediate funding pressures.
The implications of these developments are significant for the medical technology industry and for patients at risk of heart attacks. HeartBeam's platform technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025, has the potential to redefine cardiac health management. By enabling physicians to identify cardiac health trends and acute conditions remotely, the technology could significantly reduce the time to diagnosis and treatment for heart attack patients, potentially saving lives and reducing healthcare costs.
According to the company, the HeartBeam System with 12-Lead ECG synthesis software is intended for arrhythmia assessment, as detailed in its cleared indications for use. The company holds over 20 issued patents related to its technology, underscoring its commitment to innovation and intellectual property protection. As HeartBeam continues to advance its clinical programs and commercial rollout, the healthcare community will be watching closely to see how this technology impacts patient outcomes and the broader landscape of cardiac care.
For more information about HeartBeam and its recent updates, visit the company's newsroom at https://ibn.fm/BEAT or review the full press release at https://ibn.fm/QjrtT. The company's cleared indications for use can be found at https://www.heartbeam.com/indications.
